Skip to Main content Skip to Navigation
Master Thesis

Les inhibiteurs de la PCSK9 sont-ils une alternative dans la prise en charge de l'hypercholestérolémie ?

Abstract : Cardiovascular diseases are the leading cause of death worldwide and also an important cause of morbidity. Therefore, we have to treat all the cardiovascular risk factors – including hypercholesterolemia- to prevent them. A new therapeutic class, the PCSK9 inhibitors, has been approved in hypercholesterolemia by the FDA and EMA in 2015. There are currently two drug of this class on the market: PRALUENT® and REPATHA®. The mode of action of the PCSK9 inhibitors is different from the one of current treatments. Indeed, they inhibit a newly discovered protein called PCSK9 which is involved in the decrease of recycled LDL-R at the surface of the hepatocytes. PCSK9 inhibitors arrive on a market which is dominated by the statins and in a skeptical atmosphere about the role of cholesterol in cardiovascular diseases and on the efficacy of statins. PCSK9 inhibitors seem to be a great alternative to current treatments in terms of reduction of LDL-C level, except the statins. Indeed, in the majority of PCSK9 inhibitors’ clinical studies, patients receive PCSK9 inhibitors in combination with statins; therefore it’s very complicated to compare the two therapeutic classes. This new class is a promising drug for patients with familial hypercholesterolemia who don’t reach their LDL-C goal or who are statin-intolerant, and also for high cardiovascular risk patients. Nevertheless, the main obstacles to the development of PCSK9 inhibitors are the lack of morbi-mortality data and their expensive cost.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [81 references]  Display  Hide  Download
Contributor : Jean-Hugues Morneau <>
Submitted on : Friday, April 28, 2017 - 4:44:40 PM
Last modification on : Wednesday, July 15, 2020 - 8:56:03 AM
Long-term archiving on: : Saturday, July 29, 2017 - 1:43:15 PM


  • HAL Id : dumas-01516134, version 1


Mathilde Besson. Les inhibiteurs de la PCSK9 sont-ils une alternative dans la prise en charge de l'hypercholestérolémie ?. Sciences pharmaceutiques. 2017. ⟨dumas-01516134⟩



Record views


Files downloads